secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-09-23T12:25:34+00:00
Accession:  0001437749-26-031005
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin secures Mexican patent for lung-targeted liposomal Annamycin through 2040
--------------------------------------------------------------------------------

- Mexican Patent Office granted Patent No. 436849 for lung-targeted liposomal Annamycin; expires Nov 23, 2040.
- Patent strengthens global IP for Annamycin, now in pivotal MIRACLE trial for relapsed/refractory AML.
- Issued 888,400 shares via ATM in Sept 2026 for $0.48M gross proceeds; shares outstanding now 20,385,780.
- Series I warrant exercise price reduced from $0.75 to $0.51 per share due to anti-dilution after ATM issuance.
- CEO Walter Klemp cites patent as reinforcing long-term commercial potential of Annamycin platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/0001437749-26-031005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/mbrx20260922_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer